This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $41.52, representing a -1% change from its previous close.
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $44.03, signifying a -1.21% move from its prior day's close.
New Strong Sell Stocks for March 18th
by Zacks Equity Research
ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.
Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 1.15% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $51.91, denoting a +1.29% change from the preceding trading day.
Wall Street Bulls Look Optimistic About Amphastar (AMPH): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.
Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) reachead $55.51 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $55.61, denoting a +1.85% change from the preceding trading day.
Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $52.35, marking a -0.85% move from the previous day.
Amphastar Pharmaceuticals (AMPH) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $54.94, indicating a -0.81% shift from the previous trading day.
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree
by Zacks Equity Research
Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree are part of the Zacks top Analyst Blog.
5 Top Growth Stocks to Buy as Recession Fears Subside
by Tirthankar Chakraborty
Invest in growth stocks such as Amphastar Pharmaceuticals (AMPH), Abercrombie & Fitch (ANF), Cameco (CCJ), CyberArk Software (CYBR) and LendingTree (TREE) as the U.S. economy defies recession fears.
Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's
by Zacks Equity Research
Amphastar, Teva and Dr. Reddy's have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $55.45, representing a -0.84% change from its previous close.
Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.
Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $56.14, representing a +1.15% change from its previous close.
Centene (CNC) Sells Circle Health to Boost Managed Care Business
by Zacks Equity Research
Centene (CNC) concludes the divestiture of Circle Health to expand its core Managed Care business. Additionally, its plan members will enjoy continued access to Kroger's pharmacy network in 2024.
Snap these 4 Top-Ranked Liquid Stocks to Drive Solid Returns
by Vaishali Doshi
Here are four top-performing liquid stocks, American Public Education (APEI), Amphastar Pharmaceuticals (AMPH), GigaCloud (GCT) and Oceaneering International (OII), which investors can add to their portfolio to boost returns.